These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

556 related articles for article (PubMed ID: 30871560)

  • 1. The natural history of progressive fibrosing interstitial lung diseases.
    Kolb M; Vašáková M
    Respir Res; 2019 Mar; 20(1):57. PubMed ID: 30871560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
    Lamb YN
    Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and Incidence of Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype in the United States Estimated in a Large Claims Database Analysis.
    Olson AL; Patnaik P; Hartmann N; Bohn RL; Garry EM; Wallace L
    Adv Ther; 2021 Jul; 38(7):4100-4114. PubMed ID: 34156606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases.
    Fischer A; Distler J
    Clin Rheumatol; 2019 Oct; 38(10):2673-2681. PubMed ID: 31423560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases.
    Wollin L; Distler JHW; Redente EF; Riches DWH; Stowasser S; Schlenker-Herceg R; Maher TM; Kolb M
    Eur Respir J; 2019 Sep; 54(3):. PubMed ID: 31285305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
    Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
    Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry.
    Hambly N; Farooqi MM; Dvorkin-Gheva A; Donohoe K; Garlick K; Scallan C; Chong SG; MacIsaac S; Assayag D; Johannson KA; Fell CD; Marcoux V; Manganas H; Morisset J; Comes A; Fisher JH; Shapera S; Gershon AS; To T; Wong AW; Sadatsafavi M; Wilcox PG; Halayko AJ; Khalil N; Cox G; Richeldi L; Ryerson CJ; Kolb M
    Eur Respir J; 2022 Oct; 60(4):. PubMed ID: 35273032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib.
    Makino S
    Mod Rheumatol; 2021 Jan; 31(1):13-19. PubMed ID: 32964766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Care patterns of patients with chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype.
    Nili M; Singer D; Hanna M
    BMC Pulm Med; 2022 Apr; 22(1):153. PubMed ID: 35459138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progressive Fibrosing Interstitial Lung Diseases: Prevalence and Characterization in Two Italian Referral Centers.
    Faverio P; Piluso M; De Giacomi F; Della Zoppa M; Cassandro R; Harari S; Luppi F; Pesci A
    Respiration; 2020; 99(10):838-845. PubMed ID: 33264777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs).
    Spagnolo P; Distler O; Ryerson CJ; Tzouvelekis A; Lee JS; Bonella F; Bouros D; Hoffmann-Vold AM; Crestani B; Matteson EL
    Ann Rheum Dis; 2021 Feb; 80(2):143-150. PubMed ID: 33037004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrosing interstitial lung diseases: knowns and unknowns.
    Cottin V; Wollin L; Fischer A; Quaresma M; Stowasser S; Harari S
    Eur Respir Rev; 2019 Mar; 28(151):. PubMed ID: 30814139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of clinical courses and mortality of connective tissue disease-associated interstitial pneumonias and chronic fibrosing idiopathic interstitial pneumonias.
    Yıldırım F; Türk M; Bitik B; Erbaş G; Köktürk N; Haznedaroğlu Ş; Türktaş H
    Kaohsiung J Med Sci; 2019 Jun; 35(6):365-372. PubMed ID: 30913371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases.
    Cottin V; Hirani NA; Hotchkin DL; Nambiar AM; Ogura T; Otaola M; Skowasch D; Park JS; Poonyagariyagorn HK; Wuyts W; Wells AU
    Eur Respir Rev; 2018 Dec; 27(150):. PubMed ID: 30578335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline characteristics and comorbidities in the CAnadian REgistry for Pulmonary Fibrosis.
    Fisher JH; Kolb M; Algamdi M; Morisset J; Johannson KA; Shapera S; Wilcox P; To T; Sadatsafavi M; Manganas H; Khalil N; Hambly N; Halayko AJ; Gershon AS; Fell CD; Cox G; Ryerson CJ
    BMC Pulm Med; 2019 Nov; 19(1):223. PubMed ID: 31771541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases.
    Brown KK; Inoue Y; Flaherty KR; Martinez FJ; Cottin V; Bonella F; Cerri S; Danoff SK; Jouneau S; Goeldner RG; Schmidt M; Stowasser S; Schlenker-Herceg R; Wells AU
    Respirology; 2022 Apr; 27(4):294-300. PubMed ID: 35224814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence.
    Richeldi L; Varone F; Bergna M; de Andrade J; Falk J; Hallowell R; Jouneau S; Kondoh Y; Morrow L; Randerath W; Strek M; Tabaj G
    Eur Respir Rev; 2018 Dec; 27(150):. PubMed ID: 30578333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importance of chest HRCT in the diagnostic evaluation of fibrosing interstitial lung diseases.
    Torres PPTES; Rabahi MF; Moreira MADC; Escuissato DL; Meirelles GSP; Marchiori E
    J Bras Pneumol; 2021; 47(3):e20200096. PubMed ID: 34076172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases.
    Cottin V; Richeldi L; Rosas I; Otaola M; Song JW; Tomassetti S; Wijsenbeek M; Schmitz M; Coeck C; Stowasser S; Schlenker-Herceg R; Kolb M;
    Respir Res; 2021 Mar; 22(1):84. PubMed ID: 33726766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diffuse Pulmonary Ossification in Fibrosing Interstitial Lung Diseases: Prevalence and Associations.
    Egashira R; Jacob J; Kokosi MA; Brun AL; Rice A; Nicholson AG; Wells AU; Hansell DM
    Radiology; 2017 Jul; 284(1):255-263. PubMed ID: 28182861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.